US7550561B1
(en)
|
1991-05-16 |
2009-06-23 |
Cold Spring Harbor Laboratory |
p16INK4 polypeptides
|
US5889169A
(en)
*
|
1991-05-16 |
1999-03-30 |
Cold Spring Harbor Laboratory |
Cell cycle regulatory protein p16 gene
|
AU735667B2
(en)
*
|
1991-06-05 |
2001-07-12 |
Board Of Regents Acting For And On Behalf Of The University Of Michigan, The |
Targeted delivery of genes encoding secretory proteins
|
US5521291A
(en)
*
|
1991-09-30 |
1996-05-28 |
Boehringer Ingelheim International, Gmbh |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
US5981273A
(en)
*
|
1991-09-30 |
1999-11-09 |
Boehringer Ingelheim Int'l. Gmbh |
Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
|
NZ244306A
(en)
*
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
US5922859A
(en)
*
|
1992-02-01 |
1999-07-13 |
Boehringer Ingelheim International Gmbh |
Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
|
US5656609A
(en)
*
|
1992-09-24 |
1997-08-12 |
University Of Connecticut |
Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
|
US5962316A
(en)
|
1992-10-16 |
1999-10-05 |
Cold Spring Harbor Laboratory |
Cell-cycle regulatory proteins, and uses related thereto
|
US6211334B1
(en)
|
1992-10-16 |
2001-04-03 |
Cold Spring Harbor |
Cell-cycle regulatory proteins, and uses related thereto
|
WO1994011524A1
(en)
*
|
1992-11-09 |
1994-05-26 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Targetable vector particles
|
US6331390B1
(en)
|
1992-12-17 |
2001-12-18 |
Cold Spring Harbor Laboratory |
Cell-cycle regulatory proteins, and uses related thereto
|
US6043030A
(en)
*
|
1992-12-17 |
2000-03-28 |
Cold Spring Harbor Laboratory |
Cell-cycle regulatory proteins, and uses related thereto
|
ATE302854T1
(de)
|
1993-01-26 |
2005-09-15 |
Univ Pennsylvania |
Zusammensetzungen und verfahren zur verabreichung von genetischem material
|
ATE420193T1
(de)
|
1993-01-26 |
2009-01-15 |
Univ Pennsylvania |
Zusammensetzung zur verabreichung genetischen materials
|
US7001759B1
(en)
|
1993-01-26 |
2006-02-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for delivery of genetic material
|
US7691632B2
(en)
|
1993-11-18 |
2010-04-06 |
Cold Spring Harbor Laboratory |
Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression
|
US5728399A
(en)
*
|
1994-06-29 |
1998-03-17 |
University Of Conn. |
Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
|
WO1996021036A2
(en)
*
|
1994-12-30 |
1996-07-11 |
Chiron Viagene, Inc. |
Nucleic acid condensing agents with reduced immunogenicity
|
US6019980A
(en)
*
|
1995-06-07 |
2000-02-01 |
Connaught Laboratories Limited |
Nucleic acid respiratory syncytial virus vaccines
|
US5823453A
(en)
*
|
1995-11-14 |
1998-10-20 |
J & L Fiber Services, Inc. |
Refiner disc with curved refiner bars
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6162641A
(en)
*
|
1997-06-06 |
2000-12-19 |
The Regents Of The University Of Michigan |
Neuregulin response element and uses therefor
|
CA2323525C
(en)
|
1998-03-30 |
2011-03-01 |
Gerald P. Murphy |
Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
|
IL138809A0
(en)
|
1998-04-07 |
2001-10-31 |
Corixa Corp |
Fusion proteins of mycobacterium tuberculosis antigens and pharmaceutical compositions containing the same
|
US7078483B2
(en)
|
1998-04-29 |
2006-07-18 |
University Of Southern California |
Retroviral vectors including modified envelope escort proteins
|
EP2357192A1
(de)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
|
US6759393B1
(en)
|
1999-04-12 |
2004-07-06 |
Pfizer Inc. |
Growth hormone and growth hormone releasing hormone compositions
|
US7566452B1
(en)
|
1999-05-04 |
2009-07-28 |
New York University |
Cancer treatment with endothelin receptor antagonists
|
WO2000069898A2
(en)
|
1999-05-14 |
2000-11-23 |
Arbor Vita Corporation |
Molecular interactions in allergy cells
|
WO2001036604A2
(en)
|
1999-11-18 |
2001-05-25 |
Corvas International, Inc. |
Nucleic acids encoding endotheliases, endotheliases and uses thereof
|
EP2210948A3
(de)
|
1999-12-10 |
2010-10-06 |
Life Technologies Corporation |
Verwendung von mehrfachen Rekombinationsstellen mit einzigartiger Spezifizität beim Rekombinationsklonen
|
AU2002219944B2
(en)
|
2000-11-28 |
2008-02-21 |
Medimmune, Llc |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US7700341B2
(en)
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
CA2413160A1
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
KR20120053525A
(ko)
|
2000-06-16 |
2012-05-25 |
캠브리지 안티바디 테크놀로지 리미티드 |
면역특이적으로 BLyS에 결합하는 항체
|
EP2065052A3
(de)
|
2000-08-30 |
2009-08-19 |
Pfizer Products Inc. |
Anti-IgE Vakzine
|
US20040018194A1
(en)
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
EP2341060B1
(de)
|
2000-12-12 |
2019-02-20 |
MedImmune, LLC |
Moleküle mit längeren Halbwertszeiten, Zusammensetzungen und deren Verwendung
|
US8231878B2
(en)
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
EP1478751A4
(de)
|
2001-03-30 |
2005-10-19 |
Avigenics Inc |
Lysozym-promotor in vögeln
|
US7541512B2
(en)
|
2001-03-30 |
2009-06-02 |
Synageva Biopharma Corp. |
Avians containing a lysozyme promoter transgene
|
US7176300B2
(en)
|
2001-03-30 |
2007-02-13 |
Avigenics, Inc. |
Avian lysozyme promoter
|
DE60236646D1
(de)
|
2001-04-13 |
2010-07-22 |
Human Genome Sciences Inc |
Anti-VEGF-2 Antikörper
|
FI116851B
(fi)
|
2001-05-03 |
2006-03-15 |
Fit Biotech Oyj Plc |
Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
|
JP2003047482A
(ja)
|
2001-05-22 |
2003-02-18 |
Pfizer Prod Inc |
非アナフィラキシー誘発性IgEワクチン
|
WO2002097033A2
(en)
|
2001-05-25 |
2002-12-05 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
GB0113552D0
(en)
*
|
2001-06-05 |
2001-07-25 |
Secr Defence |
Vaccines
|
EP1404842A2
(de)
|
2001-06-29 |
2004-04-07 |
Novartis AG |
Screeningverfahren für perv und dessen verwendung
|
US20030138434A1
(en)
*
|
2001-08-13 |
2003-07-24 |
Campbell Robert L. |
Agents for enhancing the immune response
|
US7550650B2
(en)
|
2001-09-18 |
2009-06-23 |
Synageva Biopharma Corp. |
Production of a transgenic avian by cytoplasmic injection
|
US6875588B2
(en)
|
2001-11-30 |
2005-04-05 |
Avigenics, Inc. |
Ovomucoid promoter and methods of use
|
US7294507B2
(en)
|
2001-11-30 |
2007-11-13 |
Avigenics, Inc. |
Ovomucoid promoters and methods of use
|
US7335761B2
(en)
|
2001-11-30 |
2008-02-26 |
Avigenics, Inc. |
Avian gene expression controlling regions
|
EP1563302B1
(de)
|
2002-02-13 |
2011-09-14 |
American Diagnostica, Inc. |
Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten
|
US7135562B2
(en)
|
2002-03-14 |
2006-11-14 |
University Of Cincinnati |
Avian iFABP gene expression controlling region
|
JP2005535572A
(ja)
|
2002-04-12 |
2005-11-24 |
メディミューン,インコーポレーテッド |
組換え抗インターロイキン−9抗体
|
EP2371389A3
(de)
|
2002-08-14 |
2012-04-18 |
MacroGenics, Inc. |
FC-Gamma-RIIB-spezifische Antikörper und Verwendungsverfahren davon
|
US7544499B2
(en)
|
2002-12-16 |
2009-06-09 |
Halozyme, Inc. |
Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof
|
EP2368578A1
(de)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
|
WO2004071462A2
(en)
|
2003-02-12 |
2004-08-26 |
Johns Hopkins University |
Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
BRPI0408116B1
(pt)
|
2003-03-05 |
2022-09-20 |
Halozyme, Inc |
Polipeptídeos de hialuronidase solúveis conjugados a polímero, composições farmacêuticas compreendendo polipeptídeos ph20 solúveis, seus usos e processo de preparação, e ácidos nucléicos que codificam polipeptídeos de hialuronidase solúveis
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7354584B2
(en)
|
2003-04-11 |
2008-04-08 |
Medimmune, Inc. |
Recombinant IL-9 antibodies
|
US8183011B2
(en)
|
2003-06-13 |
2012-05-22 |
University Of Medicine And Dentistry Of New Jersey |
RNA interferases and methods of use thereof
|
JP2008500005A
(ja)
|
2003-07-15 |
2008-01-10 |
バロス リサーチ インスティテュート |
癌及び感染症の免疫療法のための組成物及び方法
|
WO2005014795A2
(en)
|
2003-08-08 |
2005-02-17 |
Genenews Inc. |
Osteoarthritis biomarkers and uses thereof
|
EP2272566A3
(de)
|
2003-08-18 |
2013-01-02 |
MedImmune, LLC |
Humanisierung von antikörpern
|
EP1667710A2
(de)
|
2003-10-03 |
2006-06-14 |
VIB vzw |
Mittel und verfahren zur rekrutierung und identifizierung von stammzellen
|
US20050227251A1
(en)
|
2003-10-23 |
2005-10-13 |
Robert Darnell |
Method of purifying RNA binding protein-RNA complexes
|
AU2004286261B2
(en)
|
2003-10-27 |
2010-06-24 |
Merck Sharp & Dohme Llc |
Method of designing siRNAs for gene silencing
|
LT2805728T
(lt)
|
2003-12-23 |
2020-05-25 |
Genentech, Inc. |
Nauji anti-il 13 antikūnai ir jų naudojimai
|
EP1786463A4
(de)
|
2004-03-26 |
2009-05-20 |
Human Genome Sciences Inc |
Antikörper gegen nogo-rezeptor
|
EP1968565B1
(de)
|
2004-04-16 |
2015-11-18 |
Sun Baocun |
Zusammensetzungen und verfahren zur unterdrückung der angiogenese
|
US10066268B2
(en)
|
2004-05-07 |
2018-09-04 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
|
US9228008B2
(en)
|
2004-05-28 |
2016-01-05 |
Idexx Laboratories, Inc. |
Canine anti-CD20 antibodies
|
US20090325150A1
(en)
|
2004-07-30 |
2009-12-31 |
Mount Sinai School Of Medicine Of New York University |
Klf6 alternative splice forms and a germline klf6 dna polymorphism associated with increased cancer risk
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
US8809287B2
(en)
|
2004-11-15 |
2014-08-19 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for altering Wnt autocrine signaling
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
NZ556158A
(en)
|
2004-12-22 |
2010-04-30 |
Auckland Uniservices Ltd |
Trefoil factors and methods of treating proliferation disorders using same
|
ES2409686T3
(es)
|
2005-01-25 |
2013-06-27 |
Prolexys Pharmaceuticals, Inc. |
Derivados de quinoxalina como agentes antitumorales
|
CA2599589A1
(en)
|
2005-02-07 |
2006-08-17 |
Genenews,Inc. |
Mild osteoarthritis biomarkers and uses thereof
|
CA2602035C
(en)
|
2005-03-18 |
2015-06-16 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
US9296816B2
(en)
|
2005-04-15 |
2016-03-29 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
EP1896083B1
(de)
|
2005-05-17 |
2016-03-02 |
Amicus Therapeutics, Inc. |
Verfahren zur behandlung von pompe-krankheit mit 1-desoxynojirimycin und derivaten
|
WO2007005898A2
(en)
|
2005-07-05 |
2007-01-11 |
Cornell Research Foundation, Inc. |
Blocking leukocyte emigration and inflammation by interfering with cd99l2
|
DK1919503T3
(en)
|
2005-08-10 |
2014-12-15 |
Macrogenics Inc |
Identification and preparation of antibodies with variant fc regions and methods of use thereof
|
US8249814B2
(en)
|
2005-10-21 |
2012-08-21 |
Genenews Inc. |
Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject
|
WO2007056227A2
(en)
|
2005-11-04 |
2007-05-18 |
Genentech, Inc. |
Use of complement pathway inhibitors to treat ocular diseases
|
AU2007235524B2
(en)
|
2006-03-30 |
2013-09-12 |
Ptc Therapeutics, Inc. |
Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
|
EP2505209A1
(de)
|
2006-06-26 |
2012-10-03 |
MacroGenics, Inc. |
Fcgamma-RIIB-spezifische Antikörper und Verfahren zu ihrer Anwendung
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
BRPI0716088B8
(pt)
|
2006-08-28 |
2021-05-25 |
Kyowa Hakko Kirin Co Ltd |
anticorpo isolado, composição, molécula de ácido nucléico isolada, vetor, método para produzir um anticorpo, hibridoma, e, kit
|
AU2007324128B2
(en)
|
2006-10-10 |
2013-10-10 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
|
EP2064335A4
(de)
|
2006-10-16 |
2011-03-30 |
Medimmune Llc |
Moleküle mit reduzierter halbwertzeit, zusammensetzungen und ihre verwendung
|
AU2007323799B2
(en)
|
2006-11-15 |
2013-07-18 |
Eli Lilly And Company |
Anti-TSG101 antibodies and their uses for treatment of viral infections
|
WO2008076960A2
(en)
|
2006-12-18 |
2008-06-26 |
Genentech, Inc. |
Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
|
EP2629094A1
(de)
|
2007-01-24 |
2013-08-21 |
Carnegie Mellon University |
Optische Biosensoren
|
CA2691434C
(en)
|
2007-06-21 |
2020-07-21 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
AU2008269689A1
(en)
|
2007-06-27 |
2008-12-31 |
Auckland Uniservices Limited |
Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
|
ES2672769T3
(es)
|
2007-08-29 |
2018-06-18 |
Sanofi |
Anticuerpos anti-CXCR5 humanizados, derivados de los mismos y sus usos
|
MX2010010387A
(es)
|
2008-04-02 |
2010-10-15 |
Macrogenics Inc |
Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
|
DK2247304T3
(en)
|
2008-04-02 |
2016-09-26 |
Macrogenics Inc |
Her2 / neu-specific antibodies and methods of use thereof
|
US7928189B2
(en)
|
2008-05-05 |
2011-04-19 |
Ottawa Health Research Institute |
PCSK9 polypeptide fragment
|
US20110081347A1
(en)
|
2008-06-04 |
2011-04-07 |
Macrogenics, Inc. |
Antibodies with Altered Binding to FcRn and Methods of Using Same
|
CN102282172B
(zh)
|
2008-09-07 |
2014-02-19 |
台湾醣联生技医药股份有限公司 |
抗伸展的ⅰ型鞘糖脂抗体、其衍生物以及用途
|
WO2010036978A2
(en)
|
2008-09-25 |
2010-04-01 |
Transgenrx, Inc. |
Novel vectors for production of growth hormone
|
US9150880B2
(en)
|
2008-09-25 |
2015-10-06 |
Proteovec Holding, L.L.C. |
Vectors for production of antibodies
|
CN106220734A
(zh)
|
2008-12-19 |
2016-12-14 |
宏观基因有限公司 |
共价双抗体及其用途
|
EP2367564A1
(de)
|
2008-12-22 |
2011-09-28 |
Universität Regensburg |
Norrin bei der behandlung von erkrankungen im zusammenhang mit erhöhter tgf-beta-aktivität
|
EP2398860B1
(de)
|
2009-02-18 |
2013-11-20 |
Carnegie Mellon University |
Gelöschte dendrimere farbstoffe zur fluoreszenzdetektion
|
WO2010118360A1
(en)
|
2009-04-09 |
2010-10-14 |
The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Production of proteins using transposon-based vectors
|
WO2010124365A1
(en)
|
2009-04-27 |
2010-11-04 |
Ottawa Hospital Research Institute |
Compositions and methods for modulating stem cells and uses thereof
|
WO2010141329A1
(en)
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
KR101778317B1
(ko)
|
2009-08-13 |
2017-09-13 |
얀센 백신스 앤드 프리벤션 비.브이. |
사람 호흡기 세포융합 바이러스(rsv)에 대한 항체 및 이용 방법
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
WO2011046457A1
(en)
|
2009-10-16 |
2011-04-21 |
Auckland Uniservices Limited |
Anti-neoplastic uses of artemin antagonists
|
CN108404123A
(zh)
|
2010-01-15 |
2018-08-17 |
康奈尔大学 |
降低细胞内蛋白质水平的方法
|
US9995679B2
(en)
|
2010-05-25 |
2018-06-12 |
Carnegie Mellon University |
Targeted probes of cellular physiology
|
TWI627964B
(zh)
|
2010-07-09 |
2018-07-01 |
傑森疫苗防護公司 |
抗-人類呼吸道融合性病毒(rsv)抗體及其使用方法
|
EP2601216B1
(de)
|
2010-08-02 |
2018-01-03 |
MacroGenics, Inc. |
Kovalente diabodies und deren verwendung
|
WO2012092299A1
(en)
|
2010-12-27 |
2012-07-05 |
Brown University |
Therapeutic and diagnostic methods involving biglycan and utrophin
|
AU2012259162C1
(en)
|
2011-05-21 |
2020-05-21 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
ES2690305T3
(es)
|
2011-09-16 |
2018-11-20 |
Ottawa Hospital Research Institute |
Composiciones de Wnt7a y métodos de utilización de las mismas
|
DK2814844T3
(da)
|
2012-02-15 |
2017-11-13 |
Novo Nordisk As |
Antistoffer, der binder og blokerer udløsende receptor udtrykt på myeloide celler-1 (trem-1)
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
RS57827B1
(sr)
|
2012-02-15 |
2018-12-31 |
Novo Nordisk As |
Antitela koja vezuju protein 1 prepoznavanja peptidoglikana
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
US9944685B2
(en)
|
2012-07-02 |
2018-04-17 |
Medizinische Universität Wien |
Complement split product C4d for the treatment of inflammatory conditions
|
WO2014120975A1
(en)
|
2013-02-01 |
2014-08-07 |
California Institute Of Technology |
Antibody-mediated immunocontraception
|
EP3110974A4
(de)
|
2014-02-24 |
2018-01-24 |
Celgene Corporation |
Verfahren zur verwendung eines aktivators von cereblon für neuronale zellexpansion und behandlung von erkrankungen des zentralnervensystems
|
JP6832709B2
(ja)
|
2014-05-16 |
2021-02-24 |
メディミューン,エルエルシー |
新生児Fc受容体結合が改変されて治療および診断特性が強化された分子
|
US9458464B2
(en)
|
2014-06-23 |
2016-10-04 |
The Johns Hopkins University |
Treatment of neuropathic pain
|
CN106536559B
(zh)
|
2014-07-17 |
2021-04-27 |
诺和诺德股份有限公司 |
定点诱变trem-1抗体以降低黏度
|
CN107429075B
(zh)
|
2014-11-17 |
2022-11-01 |
卡内基梅隆大学 |
可激活的双组份光敏剂
|
US10729790B2
(en)
|
2015-05-26 |
2020-08-04 |
Salk Institute For Biological Studies |
Motor neuron-specific expression vectors
|
US20190145961A1
(en)
|
2016-04-20 |
2019-05-16 |
Washington University |
Ppar agonist or lxr agonist for use in the treatment of systemic lupus erythematosus by modulation of lap activity
|
SG11202009625WA
(en)
|
2018-04-02 |
2020-10-29 |
Bristol Myers Squibb Co |
Anti-trem-1 antibodies and uses thereof
|
IL303969A
(en)
|
2021-01-24 |
2023-08-01 |
David Forrest Michael |
ugh
|
WO2023131901A1
(en)
|
2022-01-07 |
2023-07-13 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|